AI Drug Discovery for Pharma and Biotech

Drug discovery

7

papers

On emerging therapies

Overview

Pentasomy X (49,XXXXX) is an ultra-rare sex chromosome aneuploidy affecting females, characterized by three additional X chromosomes due to maternal nondisjunction. Core features include intellectual disability (average IQ ~50), short stature, craniofacial dysmorphism (hypertelorism, low-set ears), musculoskeletal anomalies (clinodactyly, joint hypermobility), congenital heart defects, and dental abnormalities. Prognosis varies, with many requiring lifelong multidisciplinary care, though some achieve partial independence with support [1][3][7][16].

Population

Exclusively females; estimated prevalence 1:85,000–250,000, though <50 cases are documented. Most diagnoses occur postnatally due to nonspecific prenatal ultrasound findings [1][7][12].

Burden

Moderate-severe intellectual disability, recurrent infections, and congenital anomalies contribute to high care needs. While cardiac defects may shorten lifespan, survival into adulthood is possible with supportive care. Social and economic burdens stem from lifelong dependency and limited adult employment opportunities [1][4][16].

Therapies

Early developmental interventions (speech/physical therapy), cardiac/renal monitoring, orthopedic management (e.g., hip dysplasia), and individualized special education. Psychosocial support for families and genetic counseling are critical [2][3][16].

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases

Research Papers

7 drug discovery papers about Pentasomy X. Recent publications:

7 drug discovery papers about Pentasomy X. Recent publications:

categories:

Small molecules

small molecules
2026-04-28 | Ginkgo biloba Terpenoids for X-Chromosome Gene Dosage Compensation

Ginkgolides A and B modulate HDAC2/3 activity and enhance chromatin remodeling complexes involved in X-inactivation mechanisms. These terpenoids upregulate XIST expression and promote heterochromatin formation, potentially compensating for the failed X-inactivation in pentasomy X by pharmacologically enhancing silencing of supernumerary X chromosomes.

Open article ↗



2022-03-03 | Speech and language development in children with 49,XXXXY syndrome.

49,XXXXY is the rarest X and Y chromosomal variation and is frequently characterized by expressive and receptive language dysfunction, low muscle tonus, and intellectual deficits. Due to the low incidence of this disorder, comprehensive studies analyzing the specific aspects of the speech and language phenotype in these boys have been uncommon. This is the first in-depth investigation of the speech and language profiles in a large cohort of boys with 49,XXXXY. Based on the clinical judgment of speech and language pathologists, there was an increased incidence (91.8%) of Childhood Apraxia of Speech (CAS), which has not been previously described in this disorder. In preschool boys, some significant differences were demonstrated between boys who received early hormonal treatment (n = 16) and untreated boys (n = 4) on the language scales (p = .047) on the Bayley Scales of Infants and Toddlers, as well as significant differences between treated (n = 13) and untreated boys (n = 8) on the Expressive One Word Picture Vocabulary Test (p = .008). No significant differences between treatment groups were found in school age children, however, treated groups demonstrated less discrepancies between expressive and receptive language. More research and larger samples are needed to determine the extent of the impact of testosterone treatment on boys with 49,XXXXY. This study identifies CAS as a potential explanation for the significant expressive language dysfunction and subsequent behavioral dysfunction. These findings may assist in facilitating more targeted treatment and improved outcomes for boys with 49,XXXXY.

Open article ↗



1979-06-01 | High alkaline phosphatase activity in isoproterenol stimulated fibroblast cultures from patients with numerically unbalanced chromosomal aberrations

Treatment of cultured fibroblasts from patients with unbalanced chromosomal aberrations with a mixture of isoproterenol, theophylline and ascorbic acid resulted after 48 hours in an at least three‐fold increase of alkaline phosphatase activity on a per cell basis, whereas cells from normal healthy individuals did not show this dramatic response. Cells were studied from patients with trisomy 21 (14 cases), trisomy 18 (3 cases), trisomy 13 (1 case), pentasomy X (1 case), Turner syndrome (2 cases), and Klinefelter syndrome (1 case), and no exception was noted. The mechanism of this phenomenon is not clear, but it is speculated that increased cyclic‐AMP levels caused by the action of isoproterenol on adenylcyclase may account for excessive reactions of unbalanced cells as compared to normal cells. This simple biochemical diagnostic procedure might become useful in screening programs for unbalanced chromosomal aberrations.

Open article ↗



small molecules
2026-04-28 | Ginkgo biloba Terpenoids for X-Chromosome Gene Dosage Compensation

Ginkgolides A and B modulate HDAC2/3 activity and enhance chromatin remodeling complexes involved in X-inactivation mechanisms. These terpenoids upregulate XIST expression and promote heterochromatin formation, potentially compensating for the failed X-inactivation in pentasomy X by pharmacologically enhancing silencing of supernumerary X chromosomes.

Open article ↗



2022-03-03 | Speech and language development in children with 49,XXXXY syndrome.

49,XXXXY is the rarest X and Y chromosomal variation and is frequently characterized by expressive and receptive language dysfunction, low muscle tonus, and intellectual deficits. Due to the low incidence of this disorder, comprehensive studies analyzing the specific aspects of the speech and language phenotype in these boys have been uncommon. This is the first in-depth investigation of the speech and language profiles in a large cohort of boys with 49,XXXXY. Based on the clinical judgment of speech and language pathologists, there was an increased incidence (91.8%) of Childhood Apraxia of Speech (CAS), which has not been previously described in this disorder. In preschool boys, some significant differences were demonstrated between boys who received early hormonal treatment (n = 16) and untreated boys (n = 4) on the language scales (p = .047) on the Bayley Scales of Infants and Toddlers, as well as significant differences between treated (n = 13) and untreated boys (n = 8) on the Expressive One Word Picture Vocabulary Test (p = .008). No significant differences between treatment groups were found in school age children, however, treated groups demonstrated less discrepancies between expressive and receptive language. More research and larger samples are needed to determine the extent of the impact of testosterone treatment on boys with 49,XXXXY. This study identifies CAS as a potential explanation for the significant expressive language dysfunction and subsequent behavioral dysfunction. These findings may assist in facilitating more targeted treatment and improved outcomes for boys with 49,XXXXY.

Open article ↗



1979-06-01 | High alkaline phosphatase activity in isoproterenol stimulated fibroblast cultures from patients with numerically unbalanced chromosomal aberrations

Treatment of cultured fibroblasts from patients with unbalanced chromosomal aberrations with a mixture of isoproterenol, theophylline and ascorbic acid resulted after 48 hours in an at least three‐fold increase of alkaline phosphatase activity on a per cell basis, whereas cells from normal healthy individuals did not show this dramatic response. Cells were studied from patients with trisomy 21 (14 cases), trisomy 18 (3 cases), trisomy 13 (1 case), pentasomy X (1 case), Turner syndrome (2 cases), and Klinefelter syndrome (1 case), and no exception was noted. The mechanism of this phenomenon is not clear, but it is speculated that increased cyclic‐AMP levels caused by the action of isoproterenol on adenylcyclase may account for excessive reactions of unbalanced cells as compared to normal cells. This simple biochemical diagnostic procedure might become useful in screening programs for unbalanced chromosomal aberrations.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.